Company record · updated August 5, 2026
Turnstone Biologics Corp.: 5 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs June 12, 2023 to June 12, 2023.
5observations
1source filings
5verified rows
2023-06-12most recent as-of date
Source rails for this company: S-1 charter round (5).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2023-06-12 | Series D price per share | 2.7317 USD | — | VERIFIED | "Original Issue Price" defined for Series D | 000119312523165338 |
| 2023-06-12 | Series C price per share | 2.3513 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312523165338 |
| 2023-06-12 | Series B-2 price per share | 1.152 USD | — | VERIFIED | "Original Issue Price" defined for Series B-2 | 000119312523165338 |
| 2023-06-12 | Series B-1 price per share | 0.768 USD | — | VERIFIED | "Original Issue Price" defined for Series B-1 | 000119312523165338 |
| 2023-06-12 | Series A price per share | 1 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312523165338 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.